REG - Medpal AI PLC - Acquisition of assets from Universal Pharmacy Ltd

Medpal AIAnnouncement

01/10/2025 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251001:nRSA7022Ba&default-theme=true

RNS Number : 7022B  Medpal AI PLC  01 October 2025

 

1 October 2025

MedPal AI plc

("MedPal AI" or the "Company")

 

MedPal AI plc Acquires Assets from Universal Pharmacy Limited

 

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence
("AI") company focused on wellness management, announces the acquisition,
through its wholly owned subsidiary, MedPal Limited, of key assets from
Universal Pharmacy Limited ("Universal") (in administration) for £45,000 in
cash (the "Acquisition"). The assets acquired include a leasehold property,
goodwill, certain equipment and stock and Universal's NHS Pharmacy Contract
which is a UK Distance Selling Pharmacy (DSP) licence. The Directors consider
this licence to be strategically important as it will enable MedPal AI (via
its subsidiary Medpal Limited) to provide regulated online and mail-order
pharmaceutical services.  Completion of the Acquisition is conditional, inter
alia, upon Medpal Limited's successful application to NHS England for approval
on its fitness to practice and change of ownership in respect of the NHS
Pharmacy Contract previously held by Universal. The consideration is payable
as to £15,000 on signing the agreement and £30,000 on completion, once the
licence application has been approved.

 

In conjunction with the Acquisition, MedPal AI announces the appointment of
Mike Rudin as Director of Online Pharmacy. Mike was formerly employed by Tesco
Limited as Director of Pharmacy and Superintendent Pharmacist where he led the
establishment of the UK's largest in-store pharmacy chain, spanning 200
outlets with annual turnover over £200 million. His expertise will drive
MedPal AI's online pharmacy operations. More recently he has held senior
management positions or directorships in business services, financial,
pharmaceutical and wholesale companies.

 

MedPal AI's AI-powered app aggregates health data for personalised
recommendations, including support for weight management. The Acquisition
strategically positions MedPal AI in the rapidly growing GLP-1 agonist market
for obesity treatment, including drugs such as semaglutide (eg. Ozempic and
Mounjaro). As of September 2025, approximately 2.2 million UK adults (4.1% of
the adult population)(1) use GLP-1 drugs, with an average monthly cost of
£200 per patient(2), representing a target market opportunity exceeding £440
million in monthly revenue.

 

The Acquisition and appointment of Mike Rudin underscore MedPal AI's
commitment to innovative, AI-enhanced healthcare.

 

Jason Drummond, Chief Executive Officer of MedPal AI, said:

 

"We are delighted to have been able to make this opportunistic yet
strategically important acquisition. We will be making an investment into the
business both to support its modernisation with the latest technology and to
enable it to grow revenues rapidly. We also warmly welcome Mike Rudin as our
new Director of Online Pharmacy. As one of the experienced senior
superintendent pharmacists in the UK, Mike will be a major asset to MedPal AI
and his expertise will be instrumental in driving our online pharmacy
operations and revenues."

 

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company take
responsibility for the contents of this announcement.

 

Enquiries:

 

MedPal AI plc
 
              via Square1 Consulting

Jason Drummond, Chief Executive Officer

 

Cairn Financial Advisers LLP
 
 +44 20 7213 0880

Louise O'Driscoll/Jo Turner

 

Clear Capital Markets Limited
                                                  +44
20 3869 6080

Bob Roberts/ Nick Josh

 

Square1 Consulting
 
         +44 20 7929 5599

David Bick
 
                     +44 7831 381201

 

About MedPal AI

 

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

 

MedPal AI has a partnership agreement  with Epassi UK Limited, which will,
for a limited time, grant exclusive, zero-cost access to the MedPal AI app
across Epassi's network of 11M+ employees at major firms like Siemens and
Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to
healthcare providers, businesses, and insurers, with potential use in
insurance-linked wellness programs to reduce premiums and drive new revenue
through institutional partnerships. The Company also has a partnership
agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

(1)
https://www.kantar.com/uki/inspiration/fmcg/2025-wp-glp-1-agonists-the-next-big-disruptor-in-society
(https://www.kantar.com/uki/inspiration/fmcg/2025-wp-glp-1-agonists-the-next-big-disruptor-in-society)

(2) Compare the Cost of Weight Loss Injections in 2025 - The Best Of Health
(https://www.thebestofhealth.co.uk/health-conditions/consultants-specialists/cost-of-weight-loss-injections/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQFSAFIFEISELS